Remedy Robotics raises $62M to take its remote stroke robot through an on-site trial first
DCVC led a $62 million Series B for Remedy Robotics, whose N1 robot steers catheters for stroke treatment. The money pays for an on-site pivotal trial across the University of California network; remote procedures are planned only near the end of 2027.
DCVC led a $62 million Series B for Remedy Robotics, the San Francisco company building the N1, a robot that steers catheters through blood vessels to treat stroke and other cardiovascular emergencies, the company said on Nov. 16. UC Investments, the University of California's investment office, joined as a new investor along with Skip Capital and Hostplus, which Remedy describes as one of Australia's largest pension funds. Build Collective, Blackbird, Divergent Capital and KdT Ventures put in more.
Remedy sells the N1 as a way to treat stroke patients wherever they are, but the round pays for the robot to prove itself with the surgeon in the room first. The money goes to a planned pivotal trial across the University of California network and work toward FDA approval for neurovascular intervention, the company said. Those first trials will be on-site elective procedures, such as treating unruptured aneurysms, IEEE Spectrum reported, and remote surgeries in Australia or within the UC system come near the end of 2027. CTO Jake Sganga called the remote version "very flashy," but said "in order to get there, we believe you have to solve a meaningful problem on-premise. Otherwise, doctors simply won't use the system."
The future trial sites are already in the deal. The University of California, which put in part of the money, will host the clinical studies within a year, according to CEO David Bell, and Remedy is placing prototype N1 systems with the Australian Stroke Alliance and SVIN Mission Thrombectomy.
Newsletter
Robrief Weekly
One email a week with the robotics news that matters. Free, unsubscribe anytime.
In patients, the farthest remote case so far was across town
Remedy's human record is small. In September 2025, a neurosurgeon in Toronto used the N1 on ten consenting patients in nonemergency procedures, IEEE Spectrum reported: six from an adjoining room, two from elsewhere in the hospital and two from a different hospital across town. The procedures, which recorded angiograms, were completed nearly twice as quickly as the current standard.
The network is the harder part of teleoperated surgery to scale. Remedy targets a round-trip latency of no more than 150 milliseconds and pauses all surgical action above it. University of Washington researcher Mike Teodorescu told IEEE Spectrum that experts usually treat 100 milliseconds as a safe threshold, and that many rural communities struggle to meet it.
The case against going slow is that the remote prize has no owner yet. No robotics company has full regulatory approval for telesurgery, and no patient has been operated on remotely in the United States, IEEE Spectrum noted, while Texas-based XCath has tested a steerable guide wire for thrombectomies in Panama. Remedy, with about 25 employees, is spending its new money on the slower route.
Sources Sources verified
- #surgical-robots
- #telesurgery
- #stroke
- #series-b
Share this briefing
Know someone who follows robotics? Send it their way.
Related briefings
More in Funding & CompaniesUFORCE raises $700 million at a $6 billion valuation to build its sea, air and ground drones near allied buyers
Valor Equity Partners and Britain's National Wealth Fund co-led a $700 million Series A for UFORCE, the London-based maker of Ukraine's MAGURA sea drones and LIUT ground robots. The valuation is about six times its March level, and the money is for factories, not new products.
Tutor Intelligence raises $75 million from a16z to build robots it rents out by the hour
Tutor Intelligence, whose warehouse robots learn from remote human operators, closed a $75 million Series B led by Andreessen Horowitz. Its customers buy robot work by the hour, so much of the money pays for a fleet Tutor will own.
Eka Robotics raises $150M at a $1.45B valuation to teach robots by self-play instead of human video
Eka Robotics raised a $150 million Series A co-led by a16z and F-Prime at a $1.45 billion valuation, betting that dexterous robots can be trained in physics simulation instead of on human teleoperation data. It reports up to 1,500 pick operations per hour against a company-stated human baseline of about 600.
Newsletter
Robrief Weekly
One email a week with the robotics news that matters. Free, unsubscribe anytime.